Filtered Eyewear for Sleep Quality
Trial Summary
What is the purpose of this trial?
The aim of this study is to determine the relative effectiveness of monocular and binocular light exposures, with and without selective blue-blocking filtering, on nocturnal melatonin suppression, subjective sleepiness, and visual performance of night shift workers.
Will I have to stop taking my current medications?
Yes, you will need to stop taking melatonin supplements, beta blockers, sleep medications, and antidepressant medications to participate in this trial.
What data supports the effectiveness of the treatment Filtered Eyewear for improving sleep quality?
Is filtered eyewear safe for human use?
How does the treatment of filtered eyewear for sleep quality differ from other treatments?
Filtered eyewear, like blue-light-blocking glasses, is unique because it aims to improve sleep quality by reducing exposure to blue light in the evening, which can disrupt the body's natural sleep-wake cycle. Unlike medications or other therapies, this treatment is non-invasive and involves wearing special glasses before bedtime to help support better sleep patterns.2351112
Research Team
Mariana Figueiro, PhD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Eligibility Criteria
This trial is for night shift workers interested in how different types of eyewear might affect their sleep quality. Specific eligibility details are not provided, but typically participants would need to be healthy adults who work at night.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Study Nights
Participants undergo six 5-hour study nights with different light exposure conditions to assess melatonin suppression, subjective sleepiness, and visual performance.
Follow-up
Participants are monitored for safety and effectiveness after the study nights
Treatment Details
Interventions
- Filtered Eyewear (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor
Dr. Brendan Carr
Icahn School of Medicine at Mount Sinai
Chief Executive Officer since 2024
MD, MA, MS
Dr. Vicki LoPachin
Icahn School of Medicine at Mount Sinai
Chief Medical Officer
MD, FACP, MBA